Biocon Biologics & Viatris receive nod for Kixelle-biosimilar insulin Aspart from EC

Ganesh V
/ Categories: Trending, DSIJ News
Biocon Biologics & Viatris receive nod for Kixelle-biosimilar insulin Aspart from EC

Biocon Biologics Ltd, a subsidiary of Biocon Ltd has announced that Kixelle, a biosimilar Insulin Aspart co-developed with Viatris Inc has received marketing authorisation approval from European Commission. The authorisation granted by EC is valid in all the EU member states. 

Kixelle is a fast-acting insulin analogue prescribed for the treatment of diabetes mellitus in adults, adolescents, and children of age 1 year & above. 

The company’s stock today increased by 1.12 per cent and made an intraday high of Rs 411.30 per share at 9.19 am. 

Besides, the company reported a net profit of Rs 33 crore in Q3FY21, a decrease of 72.66 per cent. It had reported a profit of Rs 120.70 crore in Q3FY20. The company reported net sales of Rs 456.10 crore for Q3FY21, a decrease of 9.02 per cent as against the net sales of Rs 501.30 crore for Q3FY20. 

According to BSE data, the stock traded at a P/E multiple of 154.95 and a price-to-book ratio of 6.28. The stock has a 52-week high and a 52-week low of Rs 487.70 and Rs 235.80, respectively. 

On Friday, the stock of Biocon Ltd ended at Rs 407.05, up by 0.07 per cent on BSE.  

Rate this article:
4.0

Leave a comment

Add comment

DSIJ MINDSHARE

Mkt Commentary28-Mar, 2024

Multibaggers28-Mar, 2024

Interviews28-Mar, 2024

Multibaggers28-Mar, 2024

Multibaggers28-Mar, 2024

Knowledge

General26-Mar, 2024

MF25-Mar, 2024

General18-Mar, 2024

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR